Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

HAVN Life Sciences Inc. (C:HAVN)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for HAVN within the last 6 months
See all filings within the past 6 months

Company News

Jul 08, 2021 08:00 ET
HAVN Life Signs Exclusive Supply Agreement With Cube Psytech
The Company will supply naturally-derived psilocybin for the development of psilocybin microdosing health products
Read full article
Jun 29, 2021 08:00 ET
Allied Corp Signs Psilocybin Manufacturing Agreement To Produce Psilonex™ RX For What We Believe To Be The Largest Known Psilocybin Patient Cohort In The World
Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce the signing of a supply and...
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 15, 2021288,43423,943
Jun 30, 2021264,491-43,967
Jun 15, 2021308,458-443,951
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

HAVN Life Sciences Inc. is a Canada-based biotechnology company. The Company is engaged in the business of the research and development of psychopharmacological products, including the formulation of standardized psychoactive compounds derived from fungi. It operates through two divisions: HAVN Labs and HAVN Retail. HAVN Labs division is focused on development and formulation of regulated and novel psychoactive compounds. HAVN Retail division is focused on formulating and selling natural health products (NHPs) using compounds. The product lines of HAVN Retail include HAVN Immunity, HAVN Cognitive, HAVN Stress and HAVN Energy. Its formulations are being designed to target receptors and enzymes to support immune regulation, support the regulation and release of neurotransmitters that support mental cognition, to reduce stress response and to support mental energy.

See business summary



Search (past week) for $HAVN.CA

  • No tweets found